Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 5, 2001, Pages 413-416

  Friedman, Henry S ^a   Keir, Stephen T ^a   Houghton, Peter J ^b   Lawless, Amy A ^a   Bigner, Darell D ^a   Waters, Stephen J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CNS tumors; Glioblastoma multiforme; Irofulven; Nude mice; Xenografts

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; DRUG VEHICLE; IRINOTECAN; TOPOTECAN;

ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GLIOBLASTOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; SESQUITERPENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034754269     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100358     Document Type: Article

References (21)

1. Heterotransplantation of human craniopharyngiomas in athymic "nude" mice
2. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
3. The basis for current treatment recommendations for malignant gliomas
4. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents
5. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
6. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
7. Irinotecan therapy in adults with recurrent or progressive malignant glioma
8. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4[1-piperidino)-carbonyloxy camptothecin against pediatric and adult central nervous system tumor xenografts
9. Anti-tumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units
10. Preclinical evaluation of illudins as anticancer agents
11. Preclinical evaluation of illudins as anticancer agents: Basis for selective cytotoxicity
12. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdrl/gpl70 metastatic MV522 lung carcinoma xenograft
13. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft
14. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan
15. Structure and reactivity of illudins
16. On the mechanism of toxicity of illudins: The role of glutathione
17. Structure-activity relationships of illudins: Analogs with improved therapeutic index
18. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol
19. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF)
20. Multicenter phase II trial of temozolomide in patients with malignant astrocytoma at first relapse
21. Randomized, multicenter, open-label, phase II, comparative study of temozolomide and procarbazine in the treatment of patients with glioblastoma multiforme at first relapse